Last reviewed · How we verify
D+L
D+L is a combination of vitamin D and L-theanine designed to support immune function and promote relaxation.
D+L is a combination of vitamin D and L-theanine designed to support immune function and promote relaxation. Used for Immune support and general wellness.
At a glance
| Generic name | D+L |
|---|---|
| Sponsor | Sequential Medicine Ltd |
| Modality | Small molecule |
| Therapeutic area | Nutritional/Wellness |
| Phase | FDA-approved |
Mechanism of action
Vitamin D acts as an immunomodulator and supports calcium homeostasis, while L-theanine is an amino acid that promotes relaxation without sedation by modulating neurotransmitter activity. The combination is intended to provide complementary benefits for immune support and stress management in marketed formulations.
Approved indications
- Immune support and general wellness
Common side effects
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (PHASE1, PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D+L CI brief — competitive landscape report
- D+L updates RSS · CI watch RSS
- Sequential Medicine Ltd portfolio CI